COVID-19 cases are less prevalent in countries where malaria is endemic, suggesting a role for anti-malarial drugs as prophylaxis

Danya Adams, Fouad Alshaban


Almost every country across the world has felt the repercussions of the pandemic of disease termed coronavirus disease 2019 (COVID-19) caused by the novel coronavirus identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).  A recently published article points to a method of prevention and prophylaxis of COVID-19 through the use of anti-malarial drugs such as the 4-aminoquinolones:  chloroquine and hydroxychloroquine, based on their mechanisms of action against SARS-CoV-2.  This report aims to explore the correlation between COVID-19 cases and countries where malaria is prevalent using statistical means.  It is hypothesized that countries where malaria is endemic will have few cases of COVID-19 since these countries use the 4-aminoquinolone anti-malarial drugs for prophylaxis.

Statistical analysis demonstrates that the numbers and incidence of COVID-19 cases and COVID-19 related deaths are substantially lower (multiple-fold lower) in countries with the highest prevalence of malaria.  The difference between both the COVID-19 incidence rate and the COVID-19 mortality rate in malaria prevalent countries compared to COVID-19 prevalent countries is statistically significant (p = 0.02 and p = 0.04 respectively).

This study provides further evidence that anti-malaria drugs may prove essential to breaking the spread of SARS-CoV-2 and preventing COVID-19 and COVID-19 related mortality.  As the pandemic continues to evolve and doctors and researchers across the globe try to attenuate or stop the spread of SARS-CoV-2, the medical community should not overlook the potential role of the 4-aminoquinolones anti-malarial drugs, chloroquine and hydroxychloroquine, and 8-aminoquinolone anti-malaria drugs, tafenoquine and primaquine, as a prophylaxis.


coronavirus, novel coronavirus, coronavirus 2, SARS-CoV-2, 19-CoV, COVID-19, COVID, chloroquine, hydroxychloroquine, primaquine, tafenoquine, quinine, 4-aminoquinoline, 8-aminioquinoline, aminoquinolines, Aralen, Plaquenil, malaria, malarial, anti-malaria


Coronavirus 2019‐nCoV, CSSE. Coronavirus 2019‐nCoV Global Cases by Johns Hopkins CSSE. (Available from: /apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6)

Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 novel coronavirus in the United States. New England Journal of Medicine 2020; 382(10), 929-36.

Guo YR., Cao QD, Hong ZS, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Military Medical Research 2020; 7(1): 11-20.

Alshaban, F. A recommendation for the use of chloroquine, hydroxychloroquine, primaquine, or tafenoquine for prophylaxis against the 2019 novel coronavirus (COVID-19) with note to the ophthalmic considerations. Eye Reports 2020; 6(1): S7-10.

Fernando SD, Rodrigo C, Rajapakse S. Chemoprophylaxis in malaria: Drugs, evidence of efficacy and costs. Asian Pacific Journal of Tropical Medicine 2011; 4(4): 330-6.

Malaria Information and Prophylaxis, by Country [M]. (2019, March 27). Centers for Disease Control and Prevention.


This year’s world malaria report at a glance. (2018, November 19). World Health Organization.

Countries in the world by population (2020). (n.d.). Worldometer. Retrieved March 16, 2020, from

Demographics of Countries. (n.d.). Worldometer. Retrieved March 16, 2020, from

Bialek S, Boundy E, Bowen V, et al. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, February 12-March 16, 2020. Morbidity and Mortality Weekly Report MMWR 2020; 69(12), 343-6.

Velavan TP, Meyer CG. The COVID‐19 epidemic. Tropical Medicine and International Health 2020; 25(3): 278-80.



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

Eye Reports [eISSN 2039-4756] is a new Open Access, online-only, peer-reviewed journal.